CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. PORTERS FIVE FORCES ANALYSIS
3.4. REGULATION AND REIMBURSEMENT SCENARIO

3.4.1. FDA
3.4.2. Health Canada
3.4.3. CE Mark
3.4.4. Ministry of Health, Labor, and Welfare (MHLW)

3.5. MARKET SHARE ANALYSIS, 2016
3.6. MARKET DYNAMICS

3.6.1. Drivers

3.6.1.1. Emerging innovative technologies for drug delivery
3.6.1.2. Increase adoption of nanomedicine across varied applications
3.6.1.3. Rising government support and funding
3.6.1.4. Growing need of therapies that have fewer side effects and are cost effective

3.6.2. Restraints

3.6.2.1. Long approval process
3.6.2.2. Risks associated with nanomedicine (environmental impacts)

3.6.3. Opportunities

3.6.3.1. Growth of healthcare facilities in emerging economies

CHAPTER 4 NANOMEDICINE MARKET, BY APPLICATION

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. VACCINES

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. REGENERATIVE MEDICINE

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

4.4. DIAGNOSTIC IMAGING

4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast

4.5. DRUG DELIVERY

4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size and forecast

4.6. IMPLANTS

4.6.1. Key market trends
4.6.2. Growth factors and opportunities
4.6.3. Market size and forecast

4.7. OTHERS

4.7.1. Key market trends
4.7.2. Growth factors and opportunities
4.7.3. Market size and forecast

CHAPTER 5 NANOMEDICINE MARKET, BY INDICATION

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. ONCOLOGICAL DISEASES

5.2.1. Market size and forecast

5.3. INFECTIOUS DISEASES

5.3.1. Market size and forecast

5.4. CARDIOVASCULAR DISEASES

5.4.1. Market size and forecast

5.5. ORTHOPEDIC DISORDERS

5.5.1. Market size and forecast

5.6. NEUROLOGICAL DISORDERS

5.6.1. Market size and forecast

5.7. UROLOGICAL DISEASES

5.7.1. Market size and forecast

5.8. OPHTHALMOLOGICAL DISEASES

5.8.1. Market size and forecast

5.9. IMMUNOLOGICAL DISEASES

5.9.1. Market size and forecast

5.10. OTHERS

5.10.1. Market size and forecast

CHAPTER 6 NANOMEDICINE MARKET, BY MODALITY

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. TREATMENTS

6.2.1. Market size and forecast

6.3. DIAGNOSTICS

6.3.1. Market size and forecast

CHAPTER 7 NANOMEDICINE MARKET, BY REGION

7.1. OVERVIEW

7.1.1. Market size and forecast

7.2. NORTH AMERICA

7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. Market size and forecast

7.2.3.1. U.S. market size and forecast
7.2.3.2. Mexico market size and forecast
7.2.3.3. Canada market size and forecast

7.3. EUROPE

7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Market size and forecast

7.3.3.1. Germany market size and forecast
7.3.3.2. UK market size and forecast
7.3.3.3. France market size and forecast
7.3.3.4. Italy market size and forecast
7.3.3.5. Spain market size and forecast
7.3.3.6. Rest of Europe market size and forecast

7.4. ASIA-PACIFIC

7.4.1. Key market trends
7.4.2. Key growth factors and opportunities
7.4.3. Market size and forecast

7.4.3.1. India market size and forecast
7.4.3.2. China market size and forecast
7.4.3.3. Japan market size and forecast
7.4.3.4. Australia market size and forecast
7.4.3.5. Rest of Asia-Pacific market size and forecast

7.5. LAMEA

7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. Market size and forecast

7.5.3.1. Brazil market size and forecast
7.5.3.2. South Africa market size and forecast
7.5.3.3. South Arabia market size and forecast
7.5.3.4. Argentina market size and forecast
7.5.3.5. Rest of LAMEA market size and forecast

CHAPTER 8 COMPANY PROFILES

8.1. ABBOTT LABORATORIES

8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Business performance
8.1.5. Key strategic moves and developments

8.2. COMBIMATRIX CORPORATION

8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Business performance
8.2.5. Key strategic moves and developments

8.3. GENERAL ELECTRIC COMPANY

8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Business performance
8.3.5. Key strategic moves and developments

8.4. SIGMA-TAU PHARMACEUTICALS, INC.

8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Key strategic moves and developments

8.5. JOHNSON & JOHNSON PRIVATE LIMITED

8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Business performance
8.5.5. Key strategic moves and developments

8.6. MALLINCKRODT PLC

8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Business performance
8.6.5. Key strategic moves and developments

8.7. MERCK & COMPANY, INC.

8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Business performance
8.7.5. Key strategic moves and developments

8.8. LUMINEX CORPORATION

8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Business performance
8.8.5. Key strategic moves and developments

8.9. PFIZER, INC.

8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Business performance
8.9.5. Key strategic moves and developments

8.10. TEVA PHARMACEUTICAL INDUSTRIES LTD.

8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Business performance
8.10.5. Key strategic moves and developments